Literature DB >> 14687446

Sildenafil citrate does not affect cardiac contractility in human or dog heart.

Jackie Corbin1, Stephen Rannels, Doss Neal, Paul Chang, Kennard Grimes, Alfreda Beasley, Sharron Francis.   

Abstract

OBJECTIVE: This study evaluated whether sildenafil citrate, an oral treatment for erectile dysfunction and a selective inhibitor of phosphodiesterase type 5 (PDE5) with modest vasodilating properties, affects cardiac contractility in vitro. RESEARCH DESIGN AND METHODS: Slices of freshly obtained human (n = 2) or dog (n = 3) atrial appendage were suspended in organ baths containing Krebs-Ringer bicarbonate buffer (pH 7.4, 37 degrees C) bubbled continuously with 95% O2 and 5% CO2, and isometric tension was recorded using a Gould physiograph. Contractions were elicited by 1-Hz electric pacing. After 15 min of equilibration, 1 microM sildenafil was added to the bath, followed 15 min later (human and dog) by 5 microM epinephrine, an inotropic agent, and 10 min later (dog) by 88 microM 3-isobutyl-1-methylxanthine (IBMX), a nonselective PDE inhibitor. In a separate experiment, cyclic guanosine monophosphate levels and PDE, protein kinase G, and protein kinase A activities were determined.
RESULTS: Addition of 1 microM sildenafil to isolated dog or human atrial tissue had no significant effect on force of cardiac contraction, whereas epinephrine produced a robust increase in contractile force in the same muscle strip. The addition of IBMX produced a marked stimulation of contractile force in dog atrial tissue. Very low amounts of PDE5 were found in extracts of human heart, consistent with its known primary location in the smooth muscle of systemic vasculature.
CONCLUSIONS: Sildenafil is unlikely to directly produce inotropic effects on cardiac muscle in patients being treated for erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14687446     DOI: 10.1185/030079903125002522

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  23 in total

Review 1.  [Management of patients with pulmonary hypertension].

Authors:  B Preckel; S Eberl; J Fräßdorf; M W Hollmann
Journal:  Anaesthesist       Date:  2012-07       Impact factor: 1.041

Review 2.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice.

Authors:  Sebastian Uhl; Marc Freichel; Ilka Mathar
Journal:  J Vis Exp       Date:  2015-09-17       Impact factor: 1.355

Review 4.  Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

Authors:  R Pofi; D Gianfrilli; R Badagliacca; C Di Dato; M A Venneri; E Giannetta
Journal:  J Endocrinol Invest       Date:  2015-07-05       Impact factor: 4.256

5.  Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis.

Authors:  Bo Jin; Xin-Ping Luo; Huan-Chun Ni; Hai-Ming Shi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 6.  Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension.

Authors:  B R Lindman; M M Chakinala
Journal:  Int J Clin Pract Suppl       Date:  2010-11

Review 7.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

8.  Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.

Authors:  Anastacia M Garcia; Stephanie J Nakano; Anis Karimpour-Fard; Karin Nunley; Penny Blain-Nelson; Natalie M Stafford; Brian L Stauffer; Carmen C Sucharov; Shelley D Miyamoto
Journal:  Circ Heart Fail       Date:  2018-09       Impact factor: 8.790

9.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

Authors:  Manling Zhang; Norimichi Koitabashi; Takahiro Nagayama; Ryan Rambaran; Ning Feng; Eiki Takimoto; Trisha Koenke; Brian O'Rourke; Hunter C Champion; Michael T Crow; David A Kass
Journal:  Cell Signal       Date:  2008-08-26       Impact factor: 4.315

Review 10.  Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.

Authors:  Praneet Kumar; Gary S Francis; W H Wilson Tang
Journal:  Nat Rev Cardiol       Date:  2009-05       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.